Cefuroxime Axetil

Abstract

Cefuroxime axetil is a broad spectrum antibacterial agent with a pharmacokinetic profile that permits convenient twice-daily administration. The drug is an effective and well tolerated treatment in patients with various infections, including otitis media, pharyngitis, sinusitis, CAP and acute exacerbations of chronic bronchitis. Cefuroxime axetil proved effective as a component of intravenous/oral sequential therapy in the treatment of CAP, although there are currently no dosage recommendations available for this regimen in some countries. Cefuroxime axetil may be considered as an empirical therapy for a range of community-acquired infections, including those in which beta-lactamase-producing strains of common respiratory pathogens are identified as the causative organisms. In an era of rapidly emerging bacterial resistance, empirical treatment with bacterial agents, potentially preventing the emergence of bacterial resistance to agents such as cefuroxime axetil may ensure the appropriate use of newer antibacterial agents, potentially preventing the emergence of bacterial resistance to these newer drugs.

The stability of the amorphous form of cefuroxime axetil in solid state

“…This second generation-cephalosporin is active against a wide range of Gram-positive and Gram-negative organisms and it is resistant to most ␤-lactamases. Cefuroxime axetil has only weak antimicrobial activity but after oral absorption is rapidly hydrolised to cefuroxime and for this reason its antimicrobial spectrum corresponds to that of the parent cephalosporin [1][2][3][4]. CFA in position 3 has a carbamoyl group which gives it a considerable metabolic stability, and in position 7 it has a methoxyimino group which causes its high stability to ␤-lactamase attack and together with the furyl ring contributes to the antibacterial properties of the molecule by enhancing its activity against Gram-negative bacteria.…”

Effect of Severity Disease on the Pharmacokinetics of Cefuroxime in Children with Multiple Organ System Failure

“…Cefuroxime (CXM) is a second generation cephalosporin antibiotic that is active against Gram-positive and Gram-negative bacteria 1,2) and is a cephalosporin with enhanced b-lactamase resistance.…”

Development and Validation of UV Spectrophotometric Method for the Determination of Cefuroxime Axetil in Bulk and Pharmaceutical Formulation

“…It is the first oral beta-lactam to combine high intrinsic acitivity with stability to beta-lactamase enzymes from most gram-positive and gram-negative organisms [4]. Cefuroxime exerts its bactericidal effect against a range of gram-positive and gram-negative bacteria by inhibiting the synthesis of bacterial cell wall [5][6][7]. It is a second generation oral cephalosporin antibiotic used for acute otitis media, bone and joint infections, meningitis, pharyngitis and tonsilitis, respiratory tract infections, septicemia, skin and skin structure infections [8].…”